Revised SPC: Imvaggis (estriol) 0.03 mg Pessary

SPC notes epidemiological evidence from a large meta-analysis suggests no increase in risk of breast cancer in women with no history of breast cancer taking low dose vaginally applied estrogens. It is unknown if low dose vaginal estrogens stimulate recurrence of breast cancer.

Source:

electronic Medicines compendium